Morgan Stanley downgraded Fusion Pharmaceuticals (FUSN) to Equal Weight from Overweight with a price target of $21, up from $10, after Fusion agreed to be acquired by AstraZeneca (AZN) for $21 per share in cash payable at deal closing plus a contingent value right, or CVR, for a maximum potential contingent value of $2.4B.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on FUSN:
- UK Stocks: AstraZeneca (AZN) Expands Cancer Portfolio with Fusion Pharma Acquisition
- Fusion Pharmaceuticals’ Acquisition and Future Focus Shift
- Fusion Pharmaceuticals to be Acquired by AstraZeneca, Accelerating Development of Next-Generation Radioconjugates to Treat Cancer
- Fusion Pharmaceuticals Inc (FUSN) Q4 Earnings Cheat Sheet
- 3 Best Stocks to Buy Now, 3/5/2024, According to Top Analysts